Huya Bioscience Enters Into U.S., European Deals That Could Help Channel Innovative Chinese Drugs Into Pipelines Of International Pharma Outfits
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In transactions that could help channel innovative Chinese drugs into the pipelines of global pharmaceutical outfits, Huya Bioscience International has signed separate deals with the U.S.-headquartered Abbott Laboratories and the Belgian-based Solvay Pharmaceuticals to identify lead compounds for potential licensing agreements